Close menu




May 12th, 2021 | 11:00 CEST

wallstreet:online, Deutsche Bank, Alibaba - Shares with potential

  • Investments
Photo credits: pixabay.com

How to find stocks with potential? Investors should use the time of waiting to inform and educate themselves. One should think long-term and only invest in things you understand. If the masses like a stock story, be careful not to buy the highs. You should ask yourself if it is just hype or if the Company has a history. If you then find a stock that convinces you, the price does not want to come back. Then you have to wait and be patient. Today we have taken a closer look at three stocks with history, all of which have experienced a setback.

time to read: 3 minutes | Author: Armin Schulz
ISIN: DE000A2GS609 , DE0005140008 , US01609W1027

Table of contents:


    wallstreet:online - Predefined growth plan

    For years, the largest financial community in the German-speaking world was built up independently of publishers via wallstreet-online.de, finanznachrichten.de, boersennews.de and ariva.de. Since the end of 2019, the monetization process of this community has now been underway, with Smartbroker offering users low-cost securities trading.

    Growth has been rapid since then and Smartbroker currently has over 130,000 customers. This number is partly due to Corona, as people were forced to stay at home, and so some discovered their passion for the stock market, especially as there were favorable entry prices for the first time in a long time thanks to the pandemic. The phenomenon can be compared with the growth of Robinhood in the USA.

    But this is far from the end of the monetization process - it is instead at the beginning. The new CEO, Matthias Hach, wants to gain 200,000 customers by the end of the year and at the same time link the dovetailing of broker and financial community even more closely. As early as 2021, the brokerage business is expected to account for 32% of sales. Deutsche Bundesbank expects the financial market to grow by 6% per year.

    To offer the Smartbroker customers as diverse an offer as possible, a sponsoring membership with the German Derivatives Association was concluded on May 1. wallstreet:online hopes to better master the increasing regulatory requirements together with the issuers of derivatives through cooperation.

    The supervisory board in the person of Marcus Seidel also believes in the potential of the share, who bought shares for over EUR 169,000 last week alone. After reaching a high of EUR 29.70, the share consolidated to EUR 16.40 by April 12. The upward trend of the share is nevertheless intact. Currently, it is possible to buy at prices roughly where the Supervisory Board also bought in.

    Deutsche Bank - The end of the dry spell

    As a former shareholder of Deutsche Bank, one has had to endure a lot of suffering since 2007. The low point was reached on March 16, 2020, and the former flagship bank had become a restructuring case. Since then, things have been looking up bit by bit. CEO Christian Sewing announced the best result of the last 7 years in the first quarter of this year: A pre-tax profit of EUR 1.6 billion.

    Investment banking is responsible for the profit. Profit before tax increased by 134% compared to the same quarter last year, which is remarkable as revenues only increased by 34%. Profitability resulted from increased demand in IPOs and shell offerings and fixed income and currency trading.

    The after-tax return on tangible equity was 7.4% and is expected to increase further. If interest rates continue to rise, Deutsche Bank will undoubtedly benefit. Yesterday, there was also positive news that the US Department of Justice is dropping the 1MBD investigation in which Malaysia sought compensation.
    The Company is holding out for the prospect of a dividend in 2022. As long as the price remains above EUR 10.37, the share looks good from a chart perspective.

    Alibaba - Growth continues despite penalty

    Alibaba is one of the world's largest corporations, which is now also known in Europe for its trading platform. The growth knows hardly any limits, and the Company is always trying to take over new companies and thus cover more areas for the customers. Alibaba is the 'Amazon of Asia'.

    The stock has come back from its high of USD 319 to USD 211 in October. One of the reasons was a record fine imposed by the Chinese government. Rumor has it that the fine is due in part to critical statements made to the Chinese government by Alibaba founder Jack Ma.

    Alibaba invested heavily in the media sector and took over newspapers, production companies and the short news platform Weibo. When the affair of a married vice president became public via Weibo, the corporation simply censored the news showing Alibaba can control opinion to a certain extent. That is certainly a thorn in the government's side. The Company will act more cautiously in the future.

    The main business at Alibaba remains commerce, but the cloud business could also grow by 50% in 2020. However, the cloud business model is only at the beginning in China, so one can spend on further growth there. The group's growth will continue to move forward, and investors can use the setback in the share to buy and build initial positions. The share must remain above the mark of USD 211.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read